诺和诺德(NVO.US)涨逾4% 英批准Wegovy7.2毫克高剂量肥胖治疗方案

Core Viewpoint - Novo Nordisk's stock rose over 4% to $59.49 following the approval of a higher dosage for its weight loss drug Wegovy by the UK drug regulatory agency [1] Group 1: Drug Approval - The UK Medicines and Healthcare products Regulatory Agency approved an increase in the maximum weekly dosage of Wegovy to 7.2 mg [1] - This new dosage can be administered in three injections, providing more treatment options for healthcare providers and patients [1] - The approval breaks the previous dosage limit of 2.4 mg, enhancing the flexibility in treatment plans for obesity patients [1]